Galvanize Therapeutics, Inc. news
SAN CARLOS, California, September 20, 2021 — Galaxy Medical announced today the initiation of the SPACE-AF study with enrollment of the first two patients at Southlake Regional Health Centre in Newmarket, Canada. In the study, the CENTAURI Pulsed Electric Field (PEF) ablation system will be used to ablate both the pulmonary veins and posterior walls in patients with persistent atrial fibrillation (AF). Recently, Galaxy has also enrolled additional subjects in the ECLIPS
SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF
90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and mapping systems from Boston Scientific, Biosense Webster and Abbott.
The ECLIPSE-AF Trial launched in Se
SAN CARLOS, California, July 22, 2021 — Galaxy Medical announced today that the 90 day remapping results of its ECLIPSE-AF study will be featured at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27th. Ante Ani, M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study will deliver the presentation.
The ECLIPSE-AF Trial launched in September 2020 to study the acut
SAN CARLOS, California, April 22, 2021 — Galaxy Medical announced today that the acute results of its Europe-focused ECLIPSE-AF study will be featured during the upcoming EHRA Congress in a innovative Technology presentation on April 25th by Ante Ani , M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study.
The ECLIPSE-AF Trial launched in September 2020 to study the acute safety of Ga
SAN CARLOS, California, April 6, 2021 — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. Under the terms of the agreement, Galaxy will pursue US regulatory approval for ALPHA1 in support of eventual commercialization of the CENTAURI PEF System.
For 40 yea